oral LNC docetaxel / Matinas - LARVOL DELTA

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation (GlobeNewswire) - "Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel....Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-docetaxel."

Preclinical • Oncology • Solid Tumor

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model (GlobeNewswire) - "Matinas BioPharma Holdings, Inc...announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors....Efficacy: Anti-tumor effect of daily oral LNC docetaxel in both the high-dose and low-dose arms were comparable to IV docetaxel with statistically significant reductions in tumor volume compared with untreated controls at Day 14 (high dose oral LNC -63%; low dose oral LNC -57%; IV docetaxel -68%), and similar reductions in tumor weight at Day 14; Safety: No systemic toxicities were noted. Body weight was stable over treatment duration and hematologic parameters were similar to untreated controls."

Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor